Second Life for Gene Therapy; Takeda Phase 2/3 Win; UK Cancer Biotech's $83M
A Cleveland‑based biotech announced a revamped gene‑therapy platform that could give a previously stalled program a second chance, while Takeda disclosed positive Phase 2/3 results for its oncology candidate. Across the Atlantic, a UK cancer‑focused biotech raised roughly $83 million to accelerate its pipeline. Additional highlights include a blood test that may predict Wegovy responders, Viridian’s thyroid‑eye disease drug clearing another Phase 3 hurdle, and Ideaya shedding two assets returned from GSK.
Swiss Manufacturing, Biotech Industry so Far Unfazed by Geopolitics
Swiss pharmaceutical manufacturing remains stable despite looming US tariff threats and broader geopolitical tensions. Industry leaders say output levels and export volumes have held steady through 2023, while biotech firms continue robust R&D spending. Analysts note that some multinational drugmakers...
Vertex Drops mRNA Cystic Fibrosis Program over 'Tolerability' Issues
Vertex Pharmaceuticals announced it is halting development of its mRNA‑based cystic fibrosis (CF) therapy after encountering tolerability and delivery challenges. The decision follows similar setbacks at other biotech firms pursuing mRNA treatments for CF. Vertex will refocus resources on its...
FDA Search for New CBER Head Focused on Small Group of Final Candidates
The U.S. Food and Drug Administration has narrowed its hunt for a new head of the Center for Biologics Evaluation and Research (CBER) to three or four finalists. CBER is the agency’s hub for overseeing vaccines, blood products, and emerging...
Biotech Has a New Startup Model: Small Team, Big Check and Chinese Assets
A wave of biotech startups is emerging that forgos deep‑science platforms in favor of lean teams, mega‑size venture checks and strategic Chinese assets such as patient data, manufacturing capacity, and regulatory pathways. These companies raise $150‑$250 million in Series A or B...
Windward Bio Gets $165M to Take China-Derived Drug Into Phase 3 Asthma Trial
Swiss biotech Windward Bio announced a $165 million financing round to propel two China‑origin experimental drugs into late‑stage development, including a Phase 3 trial for a novel asthma therapy. The capital comes from a blend of venture capital, strategic pharma investors, and...
UCB Bets $2 Billion on Candid's T Cell Engager Ambitions
UCB, the Belgian pharmaceutical group, has entered a $2 billion agreement with Candid Biotechnology to co‑develop and commercialize T‑cell engager therapies targeting autoimmune diseases. The deal provides Candid with an upfront cash payment, equity stake, and milestone‑based funding, while granting UCB...
Moderna in Talks with FDA over Phase 4 Covid Vaccine Data
Moderna is actively collaborating with the U.S. Food and Drug Administration to submit Phase 4 post‑marketing data on its COVID‑19 vaccines. The company hopes the additional safety and efficacy evidence will persuade regulators to broaden the current, narrowed product labels that...
Amgen Launches Late-Stage Obesity Trial in Patients Who Switch From Rival Drugs
Amgen is initiating three Phase III trials for its long‑acting obesity injection MariTide, including a pivotal study that enrolls about 1,200 patients switching from Eli Lilly’s semaglutide or Novo Nordisk’s tirzepatide. The primary goal is a minimum 10% body‑weight loss after 68 weeks,...
Acelyrin Founder Shao-Lee Lin Emerges at Cue, as It Becomes Latest to License From China
Cue Biopharma announced a strategic reboot, appointing Acelyrin founder Shao‑Lee Lin to its executive team and unveiling a new allergy drug candidate sourced from research labs in Taiwan and mainland China. The Boston‑based company, previously focused on T‑cell immunotherapies, will...
Save the Date: Premium Subscriber-Exclusive Post-Hoc Live
Endpoints News announced a premium‑only Post‑Hoc Live event that will break down Q1 earnings after a deal‑heavy first quarter. The live session promises real‑time analysis, interactive Q&A with analysts, and deeper insight into the companies that drove the quarter’s performance....
Summit Slips on Ivonescimab's Apparent Interim Miss in Sign of Investor Frustration
Summit Therapeutics’ shares plunged almost 20% after an interim analysis of its Phase 3 trial of ivonescimab showed a statistical shortfall in a key efficacy endpoint. The miss was limited to a subgroup analysis, but investors interpreted it as a signal...
Amgen Files Update to Tavneos Label as FDA Escalates Push to Withdraw
Amgen filed a supplemental application to revise the prescribing information for its rare‑disease drug Tavneos (avacopan) as the FDA intensifies its effort to withdraw the product. The label update seeks to add new safety warnings and monitoring requirements after the...
Seaport, Hemab Price IPOs, While Avalyn Soars in Nasdaq Debut
Three biotech companies priced their initial public offerings between Thursday and Friday, collectively raising more than $850 million. Seaport Therapeutics secured $225 million at $20 per share, while Hemab Therapeutics attracted $210 million at $18 per share. Avalyn Pharma led the pack with...
Boehringer Appoints Pharma Veteran for Corporate Affairs Post; BlueRock CSO Heads for the Exit
Boehringer Ingelheim has appointed Christie Bloomquist as senior vice president of corporate affairs for its U.S. human pharmaceuticals division, while also naming her president of the Boehringer Cares Foundation. Bloomquist brings more than two decades of experience in pharma regulatory...
FDA's Oncology Advisors Vote Against 'New Paradigm' In AstraZeneca Trial
The FDA’s oncology advisory committee voted 6‑3 that AstraZeneca’s late‑stage trial of camizestrant, an oral selective estrogen‑receptor degrader (SERD), did not demonstrate a clinically meaningful benefit. AstraZeneca had positioned camizestrant as a potential first‑in‑class oral therapy for hormone‑receptor‑positive metastatic breast...
AbbVie Faces Questions About Skyrizi Competition From J&J
AbbVie’s first‑quarter earnings call highlighted growing pressure on its immunology franchise as analysts probed the company’s defense against Johnson & Johnson’s upcoming IL‑23 inhibitor. Skyrizi, AbbVie’s flagship psoriasis drug, posted $1.2 billion in Q1 sales, a 12% year‑over‑year increase, but faces...
Bristol Myers Reaches a Crossroads as a Make-or-Break Year Takes Shape
Bristol Myers Squibb (BMS) is at a strategic inflection point as 2024 becomes a make‑or‑break year for the drugmaker. CEO Chris Boerner, now 2½ years in charge, must navigate a looming patent cliff on its flagship immunotherapy, integrate the recent Mirati Oncology...
Pfizer Earns Positive Phase 3 in Multiple Myeloma; ICON Overstated Revenue
Pfizer announced that its antibody‑drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression‑free survival for patients with double‑class exposed relapsed or refractory multiple myeloma. The Phase 3 trial met its primary endpoint, positioning the drug as a...
After Apellis Deal, Biogen Looks to Fill Early-Stage Pipeline
Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, adding a complement‑inhibition platform to its portfolio. While the deal closes this month, the company emphasized that its growth engine will now hinge on early‑stage development and research rather than late‑stage launches....
Chiesi Signs $1.9B Deal to Acquire KalVista and Its Approved Drug
Italian pharmaceutical group Chiesi announced a $1.9 billion cash acquisition of U.S. biotech KalVista Pharmaceuticals, paying $27 per share. KalVista brings an FDA‑approved therapy for a rare disease into Chiesi’s portfolio, bolstering its specialty drug offerings. The deal is part of...
Should Pharma Be Swinging Bigger with AI? One Top Researcher Wants to Try
Kyunghyun Cho, a leading AI researcher known for co‑authoring the attention mechanism, used his platform at the International Conference on Learning Representations to argue that pharmaceutical companies should dramatically increase AI investment. He outlined a plan for a $50 million venture...
GSK CEO Says Team Reorg Could Be in the Cards Pending Upcoming Phase 3 Readouts
GlaxoSmithKline (GSK) is banking on a slate of late‑stage Phase 3 trials slated for 2024, spanning oncology drugs and next‑generation vaccines. CEO Luke Miels warned on the first‑quarter earnings call that a series of missed readouts could trigger a reshuffle of...
MPM Has Collected Three China Drugs for Its ‘Best of Both Worlds’ Strategy
MPM BioImpact, a biotech investment firm, has finalized the acquisition of three China‑origin drug candidates as part of its "best of both worlds" strategy. The deals were brokered through its portfolio company K2 Therapeutics, which now controls three distinct programs...
FDA Debuts Plan to Collect Real-Time Clinical Trial Data
The U.S. Food and Drug Administration announced a pilot program that will collect clinical‑trial data in real time, allowing scientific reviewers to see information as it is generated. The initiative, launched on Tuesday, includes participation from major drugmakers AstraZeneca and...
Pfizer Delays Patent Cliff for Blockbuster Vyndamax
Pfizer announced a two‑year extension of market exclusivity for Vyndamax (tafamidis), pushing the expected generic launch to 2026. The extension stems from a new formulation patent and a pediatric study that grant additional protection. Vyndamax, approved for transthyretin amyloid cardiomyopathy,...
Hikma and Amarin's Generic Drug Case Heads to Supreme Court Arguments
The U.S. Supreme Court will hear arguments this week in the dispute between Hikma Pharmaceuticals and Amarin over a prescription‑strength fish‑oil pill, the first generic challenge to Amarin’s Vascepa. The case centers on whether the FDA’s bioequivalence standards and the...
Rocket's PRV Goes for $180M; Oruka Targets $500M Offering
New Jersey‑based Rocket Pharmaceuticals sold its pediatric‑disease priority‑review voucher for $180 million, setting a near‑record price for such assets. The cash infusion strengthens Rocket’s balance sheet as it advances late‑stage gene‑therapy candidates. Meanwhile, biotech firm Oruka Therapeutics announced plans to raise...
BeOne Medicines Licenses Trispecific Antibody Targeting PD-1, CTLA-4 and VEGF
BeOne Medicines, the rebranded former BeiGene, announced a licensing and option agreement to acquire a trispecific antibody that simultaneously targets PD‑1, CTLA‑4, and VEGF. The experimental biologic originates from a Chinese biotech and is positioned for development in solid‑tumor indications....
Updated: AbbVie Flirts with Popular Pan-RAS Field in up to $1.45B Option to Acquire Kestrel
AbbVie has signed a deal giving it an option to acquire Kestrel Therapeutics for up to $1.45 billion, targeting Kestrel’s pan‑RAS inhibitor platform. The agreement includes an upfront payment and milestone‑based earn‑outs tied to regulatory and commercial milestones. Kestrel’s lead candidate,...
FDA Claims Trial 'Manipulation' Tainted Approval of ChemoCentryx Drug
The FDA has accused ChemoCentryx of manipulating key efficacy data in the pivotal Phase III trial that secured approval for its rheumatoid‑arthritis drug Tavneos. The agency says the new information renders the trial "tainted" and is moving to pull the treatment...
Devoted Health’s 2025 Revenue Slips in Turbulent Medicare Advantage Market
Devoted Health reported its first revenue decline since launching Medicare Advantage plans, with 2025 revenue slipping about 5% to roughly $2.1 billion. Membership also fell 3% to an estimated 500,000 seniors, marking the first net loss of enrollees in seven years....
Investment in UK Biotechs Shows Early Signs of Recovery, Report Says
Investment in UK biotechnology firms is rebounding after a mid‑2025 slowdown, according to the BioIndustry Association. In the first quarter of 2026, equity funding reached roughly $210 million, a 75% year‑over‑year rise. The number of deals climbed to 48, and the...
FDA Unveils Three Psychedelic-Focused Commissioner Vouchers
The U.S. Food and Drug Administration announced it has issued fast‑track “commissioner vouchers” to three psychedelic‑focused companies. The agency withheld the identities of the sponsors, a move that surprised investors and analysts. The vouchers are designed to expedite regulatory review,...
Avalyn Plots $182M IPO; WHO Prequalifies Novartis' Malaria Drug
Avalyn Pharma announced plans for a $182 million initial public offering to fund the development of inhaled formulations of existing pulmonary fibrosis treatments. The capital raise aims to accelerate clinical trials and scale manufacturing capacity for its proprietary delivery platform. In...
Novartis Pulls Pluvicto Prostate Cancer Label Expansion Filing in the EU
Novartis has pulled its European Medicines Agency (EMA) application to extend the label of Pluvicto, its lutetium‑177 PSMA‑targeted radioligand therapy, into earlier‑stage prostate cancer. The drug already received approval for this indication in the United States and the United Kingdom,...
Exclusive: UC Berkeley Startup Bets on Jumping Genes for GLP-1 Gene Therapy
A UC Berkeley spin‑out is developing a gene‑therapy platform that inserts a GLP‑1‑producing cassette into patients' cells using a jumping‑gene (transposon) system. The approach seeks to turn the body into its own continuous source of the hormone, eliminating the need...
Sanofi’s Tolebrutinib Gets CHMP Backing for Certain MS Patients Despite FDA Rejection
Sanofi’s BTK inhibitor tolebrutinib received a positive opinion from the European Medicines Agency’s CHMP for treating relapsing forms of multiple sclerosis, despite a complete response letter from the U.S. FDA in December. The CHMP recommendation paves the way for a...
Pfizer’s Strategy Chief Andrew Baum Steps Down; Helus Pharma Swaps Out CEO After Two Months
Andrew Baum, former Citi analyst and Pfizer's chief strategy and innovation officer, has left his executive role but will stay on as a senior strategic advisor to CEO Albert Bourla. His exit adds to a recent series of senior departures...
Daiichi Sankyo Postpones Annual Results, Stock Dips
Daiichi Sankyo announced it will postpone the release of its fiscal year 2023 results, pushing the disclosure into early Q2 2024. The company cited the need for additional time to finalize figures amid ongoing regulatory reviews of its oncology pipeline....
Substance Use Disorder Biotech Tempero to Close After Earlier 'Serious' Safety Event
Tempero Bio, a biotech focused on novel treatments for substance‑use disorders, announced it will wind down operations following a serious adverse event in its late‑stage clinical trial. The company had raised more than $200 million to advance a kappa‑opioid receptor antagonist...
Novartis' Radioligand Therapy Lutathera Could Soon Face Generic Competition
Novartis’s Lutathera, the first FDA‑approved radioligand therapy for neuroendocrine tumors, recorded $1.5 billion in 2023 sales and dominates a market projected to exceed $3 billion by 2028. A generic version filed by Sandoz aims for a 2025 launch, marking the first non‑brand...
The Godmother of Silicon Valley Is Helping Launch an AI Healthcare Residency Program
Esther Wojcicki, dubbed the "Godmother of Silicon Valley," is spearheading an AI healthcare residency program aimed at equipping startup co‑founders with the technical and clinical skills needed to launch successful digital health ventures. The twelve‑month curriculum pairs entrepreneurs with seasoned...
Novo's Pill for Kids; Altimmune’s $225M Offering; Merck Teams with Google Cloud
Novo Nordisk reported that its oral GLP‑1 drug Rybelsus reduced hemoglobin A1C by 0.83% in adolescents aged 10‑17 with type‑2 diabetes after about six months of treatment. The result marks the first pediatric efficacy data for a GLP‑1 pill, expanding...
Amneal to Buy a Biosimilar Company; Samsung Bio Workers Protest
Amneal Pharmaceuticals announced it will acquire biosimilar developer Alvotech for an upfront $375 million, with additional contingent payments tied to regulatory milestones. The deal expands Amneal’s pipeline into high‑margin biologics, adding several approved and late‑stage biosimilar candidates. Concurrently, workers at Samsung...
Endpoints Wins Neal Awards for Trump and Gene Editing Coverage, JPM Event
Endpoints News earned three 2026 Neal Awards, honoring its in‑depth reporting on the pharmaceutical sector’s ties to the Trump administration, a three‑part series on gene‑editing breakthroughs, and its coverage of the JPMorgan health‑care conference. The awards, presented by the American...
Gravity Rail Raises $2.75M From Redesign Health for AI Patient Communication
Gravity Rail, an AI‑driven platform that automates patient calls, texts and follow‑up workflows, announced a $2.75 million seed round led by Redesign Health. The funding will accelerate product development and expand its go‑to‑market team. Gravity Rail’s technology aims to streamline enrollment,...
#AAN26: Roche’s Multiple Sclerosis Pill Delays Relapse, but Liver Toxicity Could Need Monitoring
Roche’s experimental multiple sclerosis pill fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, more than doubled the relapse‑free interval compared with Sanofi’s oral therapy Aubagio in a late‑stage trial. The Phase 3 data showed roughly 68% of patients remained relapse‑free at...
Medicare Indefinitely Delays Pilot Plan to Cover Weight Loss Drugs
Medicare’s Center for Medicare & Medicaid Services announced an indefinite postponement of its pilot program to cover prescription weight‑loss medications. The pilot, originally slated to test coverage for drugs such as Wegovy and Zepbound, was halted after participating insurers raised...
RFK Jr. Says China Is 'Eating Our Lunch' In Biotech Advances
HHS Secretary Robert F. Kennedy Jr. warned Congress that China is outpacing the United States in biotech, citing faster new‑drug approvals and a surge in clinical‑trial starts. He highlighted that China approved more than 70 novel therapies in 2025, compared with roughly 45...